Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine and Oxaliplatin in Resectable Pancreatic Cancer
NCT00536874Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2007
- Primary completion
- Sep 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2007; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00536874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00536874.